Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Sarclisa
Pharma
ASCO: Sanofi's Sarclisa looks to step out of J&J's myeloma shadow
Based on the data, the FDA has put Sanofi’s application for the Sarclisa-VRd combo under a priority review in first-line transplant-ineligible myeloma.
Angus Liu
Jun 3, 2024 4:00pm
ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma
Dec 12, 2023 12:00pm
Sanofi targets first-line myeloma as Sarclisa delivers trial win
Dec 7, 2023 11:26am
Sanofi's Dupixent still 'at the beginning' of its journey: exec
Apr 28, 2022 11:37am
Sanofi taps Blackstone for $300M for subcutaneous Sarclisa R&D
Mar 15, 2022 9:20am
Sanofi's Sarclisa, J&J's Darzalex clash in 4-drug myeloma trials
Dec 11, 2021 9:30am
